| 摘要 |
Compounds having the formula (I), <?in-line-formulae description="In-line Formulae" end="lead"?>Ar-(F)-(E)-(CR<SUP>3</SUP>R<SUP>4</SUP>)-(CHR<SUP>5</SUP>)<SUB>m</SUB>-(T)-(Q)-Ar<SUP>1</SUP>,<?in-line-formulae description="In-line Formulae" end="tail"?> are useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl group having one N atom and a bridge of one to two bridgehead carbon atoms; Ar and Ar<SUP>1 </SUP>are aryl or heteroaryl; F is alkylene, alkenylene, or a bond; E is -C(-O)N(R<SUP>10</SUP>)-, -SO<SUB>2</SUB>N(R<SUP>10</SUP>)-, -N(R<SUP>11</SUP>)C(-O)N(R<SUP>10</SUP>)-, -N(R<SUP>11</SUP>)SO<SUB>2</SUB>N(R<SUP>10</SUP>)-, -N(R<SUP>11</SUP>)C(-S)N(R<SUP>10</SUP>)-, -N(R<SUP>11</SUP>)C(-O)-, -N(R<SUP>11</SUP>)SO<SUB>2</SUB>-, -N(R<SUP>12</SUP>)C(-O)CH(R<SUP>13</SUP>)-, or CH(R<SUP>13</SUP>)C(-O)N(R<SUP>12</SUP>)-; Q is -C(-O)- or C<SUB>1-2</SUB>alkylene; and R<SUP>3</SUP>, R<SUP>4</SUP>, R<SUP>5</SUP>, R<SUP>9</SUP>, R<SUP>10</SUP>, R<SUP>11</SUP>, R<SUP>12</SUP>, and R<SUP>13 </SUP>are defined as set forth in the specification. |
